Butylscopolamine

Overview

Butylscopolamine (N-Butylscopolammonium Bromide; Buscopan®) is a quaternary ammonium antispasmodic and anticholinergic agent used in dogs for control of gastrointestinal smooth muscle spasm and associated abdominal discomfort.

It exerts peripheral anticholinergic effects by competitively blocking muscarinic receptors on smooth muscle, resulting in decreased gastrointestinal motility and reduced intestinal cramping. Because it is a quaternary ammonium compound, central nervous system penetration is minimal.

Mechanism of Action (MOA): Butylscopolamine inhibits muscarinic receptors in the gastrointestinal tract, leading to reduced peristalsis and decreased smooth muscle tone. It also produces mild anticholinergic effects such as increased heart rate, decreased secretions, and pupil dilation. Its clinical effects are relatively short-lived compared with atropine.

Indications

In dogs, butylscopolamine is used for the control of gastrointestinal smooth muscle spasm and associated abdominal discomfort. It is most commonly utilized in cases involving functional GI disturbances rather than obstructive disease.

• Control of diarrhea: Used to reduce intestinal hypermotility contributing to acute, noninfectious diarrhea.
• Abdominal discomfort and cramping: Helps relieve pain associated with intestinal smooth muscle spasm.
• Adjunctive GI therapy: May be incorporated into treatment protocols for functional gastrointestinal disturbances when reduced motility is desired.

Dosage (Reference)

Dog

In dogs, butylscopolamine is used for control of diarrhea and abdominal discomfort associated with gastrointestinal spasm. Dosing varies depending on whether combination or single-ingredient formulations are used.

Cat

Butylscopolamine is not recommended for use in cats.

Warnings & Precautions

Butylscopolamine (N-butylscopolammonium bromide) is an anticholinergic agent that reduces gastrointestinal motility and increases heart rate. Appropriate patient selection is essential, particularly in cases where reduced GI motility or tachycardia may be harmful.

• Ileus and obstructive disorders: Contraindicated in patients with impaction colic associated with ileus or in any condition where decreased gastrointestinal motility could worsen the clinical status.
• Glaucoma: Contraindicated due to potential mydriatic effects that may increase intraocular pressure.
• Cardiovascular compromise: Use cautiously in patients with systemic cardiovascular disease, as the drug can cause tachycardia and transient hypertension.
• Heart rate interpretation: Because transient tachycardia occurs after administration, heart rate should not be used as a reliable indicator of pain for approximately 30 minutes post-injection.
• Response to therapy: Failure to respond when used for abdominal pain may indicate a more serious condition requiring surgical intervention or more aggressive treatment.
• Pregnant or lactating animals: Safety has not been established; use is not recommended in pregnant or lactating animals.
• Species restriction: Do not use in cats.

Drug Interactions

The following drug interactions have been reported or are theoretical in animals receiving N-butylscopolammonium bromide (butylscopolamine). Concurrent use is not always contraindicated, but potential risks should be weighed and appropriate monitoring performed.

• Anticholinergic agents (e.g., atropine, glycopyrrolate):
  May produce additive anticholinergic effects, including tachycardia, decreased GI motility, reduced secretions, and mydriasis.
• Metoclopramide and other prokinetic/cholinergic-like GI drugs:
  May counteract each other’s effects on gastrointestinal smooth muscle (prokinetic stimulation vs anticholinergic inhibition).
• Xylazine:
  In healthy horses, concurrent use may result in significant hypertension and cardiac tachyarrhythmias. This combination may also falsely influence surgical decision-making and prognosis in horses with colic.

Side Effects & Overdose

Side Effects

Adverse effects of butylscopolamine are primarily related to its anticholinergic activity and are generally transient when used at labeled doses.

• Tachycardia: Transient increase in heart rate is common after IV administration.
• Hypertension: Temporary elevation in blood pressure may occur.
• Decreased gastrointestinal sounds: Reduced borborygmal sounds for approximately 20–30 minutes following IV dosing.
• Mydriasis: Transient pupil dilation may be observed.
• Decreased secretions: Dry mucous membranes due to anticholinergic effects.
• Pain assessment limitation: Heart rate cannot be used as a reliable indicator of pain for approximately 30 minutes after injection.

Overdose

In preapproval studies, horses received doses up to 10 times the recommended dose (3 mg/kg). Clinical effects were consistent with exaggerated anticholinergic activity and were generally self-limiting.

• Dilated pupils: Returned to normal within 4–24 hours.
• Tachycardia: Resolved within approximately 2 hours.
• Dry mucous membranes: Resolved within 1–2 hours.
• Inhibited gut motility: Returned to baseline within 4 hours; normal feces observed within 6 hours.
• Mild colic signs: Observed in some horses at 10× dose; resolved without further treatment.
• Management: Supportive care and monitoring are recommended. Consultation with a veterinary poison control service is encouraged in suspected overdose cases.

Key Notes

Practical clinical considerations to optimize the safe and effective use of butylscopolamine in veterinary practice:

• Rapid onset: Clinical effects occur quickly after IV administration, making it useful for short diagnostic or therapeutic interventions.
• Short duration: GI and bronchodilatory effects are brief; reassessment is important if pain recurs after initial improvement.
• Single-dose labeling: Labeled for a single IV dose; repeated dosing should only be considered with careful clinical judgment.
• Rectal examination aid: Temporary reduction in rectal tone can facilitate rectal palpation and certain diagnostic procedures.
• Bronchodilation: May provide short-term bronchodilatory benefit in horses with severe equine asthma.
• Product concentration check: Verify concentration (e.g., 20 mg/mL) before calculating dose to avoid dosing errors.
• Food animal restriction: Not approved for use in horses intended for human consumption.